Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: A prospective study

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 5, 2007, Pages 425-431

  Nahon, Pierre ^a,b   Sutton, Angela ^a,b   Rufat, Pierre ^c   Faisant, Charles ^b   Simon, Chantal ^b   Barget, Nathalie ^b   Trinchet, Jean Claude ^a,b   Beaugrand, Michel ^a,b   Gattegno, Liliane ^a,b   Charnaux, Nathalie ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL JEAN VERDIER   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chemokine; Cirrhosis; Hepatocellular carcinoma; Polymorphism

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA;

ADULT; ALCOHOL LIVER CIRRHOSIS; ALLELE; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS REGULATION; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; VIRUS ETIOLOGY;

ADULT; AGED; ALCOHOL DRINKING; CARCINOMA, HEPATOCELLULAR; CHEMOKINE CCL2; CHEMOKINES; CHEMOKINES, CXC; EPIDEMIOLOGIC METHODS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RANTES; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; TEMPERANCE;

EID: 34247155670     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3280120e2b     Document Type: Article

References (28)

1. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003; 38:S136-S149.
2. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, et al. Five survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23:45-53.
3. Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2006; 22:248-253.
4. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121-127.
5. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002; 13:143-154.
6. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003; 198:1381-1389.
7. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments with hepatitis C-infected liver. J Immunol 1999; 163:6236-6243.
8. Apolinario A, Majano PL, Alvarez-Perez E, Saez A, Lozano C, Vargas J, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 2002; 97:2861-2870.
9. Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H, et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004; 34:1164-1174.
10. Kusano F, Tanaka Y, Marumo F, Sato C. Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C. Lab Invest 2000; 80:415-422.
11. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999; 29:140-148.
12. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259:344-348.
13. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting influence of CCR2 and CCR5 variants on HIV infection and disease progression. Science 1997; 277:959-965.
14. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998; 279:389-393.
15. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Science 1996; 273:1856-1862.
16. Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R. Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 allele. Clin Chem 2005; 51:452-455.
17. Razmkhah M, Talei AR, Doroudchi M, Khalili-Azad T, Ghaderi A. Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett 2005; 225:261-266.
18. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 2004; 41:e59.
19. Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124:352-360.
20. Goulding C, Murphy A, MacDonald G, Barrett S, Crowe J, Hegarty J, et al. The CCR5-Δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54:1157-1161.
21. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2 with outcome of HCV infection. Hepatology 2003; 38:1468-1476.
22. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004; 10:S115-120.
23. Sutton A, Nahon P, Pessayre D, Rufat P, Poire A, Ziol M, et al. Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res 2006; 66:2844-2852.
24. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998; 279:389-393.
25. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001; 158:233-239.
26. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med 1999; 159:2021-2023.
27. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
28. Mühlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003; 125:1085-1093.